Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1Advanced Solid Tumors 1

Interventions

tislelizumab 3toripalimab 1tazemetostat 1sintilimab 1pembrolizumab 1osimertinib 1enzalutamide 1envafolimab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1Ultrasonography 1Specimen Handling 1Radiotherapy 1Oxaliplatin 1Off-Label Use 1Leucovorin 1Injections 1Indocyanine Green 1Immune Checkpoint Inhibitors 1Histocompatibility Testing 1Fluorouracil 1Fluorodeoxyglucose F18 1Carboplatin 1Blood Specimen Collection 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × WW Domain-Containing Oxidoreductase × 90 days × Clear all
NCT07229638 2026-03-20

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
70 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡